Filbey D, Berseus O, Lindeberg S, Wesström G
Early Hum Dev. 1987 Jan;15(1):11-20. doi: 10.1016/0378-3782(87)90096-x.
A management programme for the control and treatment of Rh0 (D) immunized during pregnancy is presented. A total of 34,650 births were registered during a 4.5 year period and included 63 D positive newborns to D-immunized mothers. The outcome of all infants has been evaluated according to the severity of the haemolytic disease. Exchange transfusion was unnecessary in 43 mild cases (68.3%). Fourteen infants (22.2%) required exchange transfusion, and in 6 severe cases (9.5%) maternal plasma exchange and exchange transfusion was performed. No detrimental effects or deaths occurred among the infants suffering from Rh haemolytic disease. We recommend that the frequency and volume of plasma exchange therapy should be individually adjusted to suit each patient and the effect monitored regularly through maternal anti-D levels using a sensitive quantitative technique.
本文介绍了一种针对孕期Rh0(D)免疫的控制与治疗管理方案。在4.5年期间共记录了34,650例分娩,其中包括63例母亲为D免疫的D阳性新生儿。所有婴儿的结局均根据溶血病的严重程度进行了评估。43例轻度病例(68.3%)无需进行换血治疗。14例婴儿(22.2%)需要进行换血治疗,6例严重病例(9.5%)进行了母体血浆置换和换血治疗。患有Rh溶血病的婴儿中未出现有害影响或死亡情况。我们建议,血浆置换治疗的频率和量应根据每位患者的情况进行个体化调整,并通过使用敏感定量技术定期监测母体抗-D水平来监测效果。